Cited by 1,987Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 60 of the 70 references it cites were found in a registry or an index.

The p53 proto-oncogene can act as a suppressor of transformation

Finlay, Cathy A., Hinds, Philip W., Levine, Arnold J.·1989·Cell

Open this paper in CoChat — free account

Abstract

DNA clones of the wild-type p53 proto-oncogene inhibit the ability of E1A plus ras or mutant p53 plus ras-activated oncogenes to transform primary rat embryo fibroblasts. The rare clones of transformed foci that result from E1A plus ras plus wild-type p53 triple transfections all contain the p53 DNA in their genome, but the great majority fail to express the p53 protein. The three cell lines derived from such foci that express p53 all produce mutant p53 proteins with properties similar or identical to transformation-activated p53 proteins. The p53 mutants selected in this fashion (transformation in vitro) resemble the p53 mutants selected in tumors (in vivo). These results suggest that the p53 proto-oncogene can act negatively to block transformation.

Integrity signals

Registry

Crossref · 10.1016/0092-8674(89)90045-7

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,302
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.
Southern, P. J., & Berg, P. R. (1982) · PubMed · Cited by 2,740
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814
Self-citation
SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene
DeCaprio, J. A., Ludlow, J. W., Figge, J., Shew, J.-Y., Huang, C.-M., Lee, W.-H., Marsilio, E., Paucha, E., & Livingston, D. M. (1988) · Cell · doi:10.1016/0092-8674(88)90559-4 · Cited by 1,459
Human Retinoblastoma Susceptibility Gene: Cloning, Identification, and Sequence
Lee, W., Bookstein, R., Hong, F., Young, L.-J., Shew, J., & Lee, E. Y.-H. P. (1987) · Science · doi:10.1126/science.3823889 · Cited by 1,417
Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product
Whyte, P., Buchkovich, K. J., Horowitz, J. M., Friend, S. H., Raybuck, M., Weinberg, R. A., & Harlow, E. (1988) · Nature · doi:10.1038/334124a0 · Cited by 1,403
Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture
Ruley, H. E. (1983) · Nature · doi:10.1038/304602a0 · Cited by 1,248

Show all 70 references

Sorted by citations

Items 401–500 of 999

The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: A review
Moodley, M., Moodley, J., Chetty, R., & Herrington, C. S. (2003) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2003.13030.x · Cited by 107
Long-term outcome of patients with perianal Paget's disease
Marchesa, P., Fazio, V. W., Oliart, S., Goldblum, J. R., Lavery, I. C., & Milsom, J. W. (1997) · Annals of Surgical Oncology · doi:10.1007/bf02303671 · Cited by 107
Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes
Rubin, S. J., Hallahan, D. E., Ashman, C. R., Brachman, D. G., Beckett, M. A., Virudachalam, S., Yandell, D. W., & Weichselbaum, R. R. (1991) · Journal of Surgical Oncology · doi:10.1002/jso.2930460108 · Cited by 107
Emerging Role of Heat Shock Proteins in Biology and Medicine
Jäättelä, M., & Wissing, D. (1992) · Annals of Medicine · doi:10.3109/07853899209149952 · Cited by 106
p53 binds to the TATA-binding protein-TATA complex
Martin, D. W., Muñoz, R. M., Subler, M. A., & Deb, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38619-3 · Cited by 106
p53 Mutations: Gains or losses?
Michalovitz, D., Halevy, O., & Oren, M. (1991) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240450108 · Cited by 107
Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53
Milne, D., Palmer, R. H., & Meek, D. W. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.21.5565 · Cited by 106
The 1995 Walter Hubert Lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene
Harris, C. C. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.47 · Cited by 107
Stable overexpression of MEN1 suppresses tumorigenicity of RAS
Kim, Y. S., Burns, A. L., Goldsmith, P. K., Heppner, C., Park, S. Y., Chandrasekharappa, S. C., Collins, F. S., Spiegel, A. M., & Marx, S. J. (1999) · Oncogene · doi:10.1038/sj.onc.1203005 · Cited by 106
Tumurigenesis by slow-transforming retroviruses—an update
van Lohuizen, M., & Berns, A. J. M. (1990) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(90)90005-l · Cited by 106
Role of p53 in Apoptosis
Canman, C. E., & Kastan, M. B. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)61068-6 · Cited by 106
neu/ERBB2 Cooperates with p53-172H during Mammary Tumorigenesis in Transgenic Mice
Li, B., Rosen, J. M., McMenamin-Balano, J., Muller, W. J., & Perkins, A. S. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3155 · Cited by 104
Life and death by P53
Elledge, R. M., & Lee, W. (1995) · BioEssays · doi:10.1002/bies.950171105 · Cited by 106
High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma.
Cesarman, E., Inghirami, G., Chadburn, A., & Knowles, D. M. (1993) · PubMed Central · Cited by 104
Simian Virus 40 Large-T Antigen Expresses a Biological Activity Complementary to the p300-Associated Transforming Function of the Adenovirus E1A Gene Products
Yaciuk, P., Carter, M. C., Pipas, J. M., & Moran, E. M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.4.2116 · Cited by 106
The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.
Slingerland, J., Jenkins, J. R., & Benchimol, S. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05744.x · Cited by 105
Grape Seed Proanthocyanidins Induce Apoptosis through p53, Bax, and Caspase 3 Pathways
Roy, A. M., Baliga, M. S., Elmets, C. A., & Katiyar, S. K. (2005) · Neoplasia · doi:10.1593/neo.04412 · Cited by 105
The Spectrum of Mutations at the p53 Locus
Levine, A. J., Wu, M. C., Chang, A., Silver, A., Attiyeh, E. F., Lin, J., & Epstein, C. B. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb12115.x · Cited by 106
Self-citation
Formation of stable p53 homotetramers and multiples of tetramers
Stenger, J. E., Mayr, G. A., Mann, K., & Tegtmeyer, P. (1992) · Molecular Carcinogenesis · doi:10.1002/mc.2940050204 · Cited by 104
Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene?
Dumaz, N., Stary, A., Soussi, T., Daya–Grosjean, L., & Sarasin, A. R. (1994) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(94)90311-5 · Cited by 104
Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival
Reinartz, J. J., George, E., Lindgren, B. R., & Niehans, G. A. (1994) · Human Pathology · doi:10.1016/0046-8177(94)90068-x · Cited by 103
Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas
Andersen, T. I., Gaustad, A., Børresen‐Dale, A., Farrants, G. W., Nesland, J. M., Ottestad, L., & Tveit, K. M. (1992) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870040203 · Cited by 103
Prognostic significance of human papillomavirus genomes (type‐16, ‐18) and aberrant expression of p53 protein in human esophageal cancer
Furihata, M., Ohtsuki, Y., Ogoshi, S., Takahashi, A., TAMIYA, T., & Ogata, T. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540211 · Cited by 102
The stress (heat shock) proteins
Hideaki, I., & Tashima, Y. (1991) · International Journal of Biochemistry · doi:10.1016/0020-711x(91)90214-8 · Cited by 102
p53 Is Covalently Linked to 5.8S rRNA
Fontoura, B. M. A., Sorokina, E. A., David, E., & Carroll, R. B. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5145 · Cited by 102
Immunohistochemical study of p53 in human lung carcinomas.
Brambilla, E. M., Gazzéri, S., Moro‐Sibilot, D., de Fromentel, C. C., Gouyer, V., Jacrot, M., & Brambilla, C. (1993) · PubMed Central · Cited by 102
Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen.
Friedman, P. N., Kern, S. E., Vogelstein, B., & Prives, C. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9275 · Cited by 102
Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts
Muganda, P. M., Mendoza, O., Hernandez, J., & Qian, Q. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8028-8034.1994 · Cited by 101
P53 Gene Alterations in Human Prostate Carcinoma
Effert, P. J., McCoy, R. H., Walther, P. J., & Liu, E. T. (1993) · The Journal of Urology · doi:10.1016/s0022-5347(17)35458-7 · Cited by 101
The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma
Joypaul, B. V., Hopwood, D., Newman, E., Qureshi, S. S., Grant, A., Ogston, S., Lane, D. P., & Cuschieri, A. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.182 · Cited by 100
Redox state regulates binding of p53 to sequence-specific DNA, but not to non-specific or mismatched DNA
Parks, D. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.6.1289 · Cited by 100
p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts.
Ogden, G. R., CHISHOLM, D. M., Kiddie, R. A., & Lane, D. P. (1992) · Journal of Clinical Pathology · doi:10.1136/jcp.45.11.1007 · Cited by 99
Analysis of p53 Mutants for Transcriptional Activity
Raycroft, L., Schmidt, J. R., Yoas, K., Hao, M., & Lozano, G. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.12.6067 · Cited by 99
Alterations of The P53 Gene Are Associated With The Progression Of A Human Prostate Carcinoma
Effert, P. J., Neubauer, A., Walther, P. J., & Liu, E. T. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37387-1 · Cited by 99
Analysis of the P53 Tumor–Suppressor Gene in Hepatocellular Carcinomas From Britain
Challen, C., Lunec, J., Warren, W., Collier, J. D., & Bassendine, M. F. (1992) · Hepatology · doi:10.1002/hep.1840160610 · Cited by 99
Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue
Inoue, Y., Frassica, F. J., Sim, F. H., Unni, K. K., Petersen, I. A., & McLeod, R. A. (2000) · Journal of Surgical Oncology · doi:10.1002/1096-9098(200009)75:1 · Cited by 96
The Loss of PIN1 Deregulates Cyclin E and Sensitizes Mouse Embryo Fibroblasts to Genomic Instability
Yeh, E. S., Lew, B. O., & Means, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505770200 · Cited by 98
Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.
Côté, R. J., Jhanwar, S. C., Novick, S., & Pellicer, À. (1991) · PubMed · Cited by 94
Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas.
Nuorva, K., Soini, Y., Kamel, D., Autio‐Harmainen, H., Risteli, L., Risteli, J., Vähäkangas, K., & Pääkkö, P. K. (1993) · PubMed Central · Cited by 98
p53 in neurodegenerative diseases and brain cancers
Checler, F., & da Costa, C. A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.009 · Cited by 99
MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor
Korkolopoulou, P., Christodoulou, P., Kouzelis, K., Hadjiyannakis, M., Priftis, A., Stamoulis, G., Seretis, A., & Thomas-Tsagli, E. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.216 · Cited by 95
p53 expression in odontogenic keratocyst epithelium
Li, T., Browne, R. M., Prime, S. S., Paterson, I. C., & Matthews, J. B. (1996) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.1996.tb01380.x · Cited by 97
Improving cancer therapy by non-genotoxic activation of p53
Laı́n, S., & Lane, D. P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00063-7 · Cited by 99
Identification of highly expressed genes in metastasis-suppressed chromosome 6/human malignant melanoma hybrid cells using subtractive hybridization and differential display
Lee, J., & Welch, D. R. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970611)71:6 · Cited by 174
Intercellular adhesions as determinants of tissue assembly and malignant invasion
Steinberg, M. S., & Foty, R. A. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199711)173:2 · Cited by 43
Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frébourg, T., Kassel, J., Lam, K. T., Gryka, M. A., Barbier, N., Andersen, T. I., Børresen‐Dale, A., & Friend, S. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6413 · Cited by 97
Mutation detection by pyrosequencing: sequencing of exons 5–8 of the p53 tumor suppressor gene
Garcia, C. A., Ahmadian, A., Gharizadeh, B., Lundeberg, J., Ronaghi, M., & Nyrén, P. (2000) · Gene · doi:10.1016/s0378-1119(00)00257-2 · Cited by 97
Mutations of the p53 gene in lymphoid leukemia
Sugimoto, K., Toyoshima, H., Sakai, R., Miyagawa, K., Hagiwara, K., Hirai, H., Ishikawa, F., & Takaku, F. (1991) · Blood · doi:10.1182/blood.v77.6.1153.1153 · Cited by 97
Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
Li, H., Zhang, J., TONG, J. H. M., Chan, A. W. H., Yu, J. Q., Kang, W., & To, K. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235999 · Cited by 100
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103
A Cellular Repressor of E1A-Stimulated Genes That Inhibits Activation by E2F
Veal, E. A., Eisenstein, M. S., Tseng, Z. H., & Gill, G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5032 · Cited by 96
p53 Mutations and Prognosis in Bladder Tumors
Uchida, Τ., Wada, C., Ishida, H., Wang, C., Egawa, S., Yokoyama, E., Kameya, T., & Koshiba, K. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67517-7 · Cited by 96
Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer
McGregor, J. M., Yu, C. C. ‐., DUBLIN, E. A., Levison, D. A., & MACDONALD, D. M. (1992) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1992.tb14841.x · Cited by 96
The involvement of oncogenes and tumor suppressor genes in the control of apoptosis
Oren, M. (1992) · Cancer and Metastasis Reviews · doi:10.1007/bf00048060 · Cited by 96
p53 mutations and histological type of invasive breast carcinoma.
Marchetti, A., Buttitta, F., Pellegrini, S., Campani, D., Diella, F., Cecchetti, D., Callahan, R., & Bistocchi, M. (1993) · PubMed · Cited by 96
P53 protein expression in lymphomas and reactive lymphoid tissue
Villuendas, R., Piris, M. A., Orradre, J. L., Mollejo, M., Algara, P., Sanchez, L., Martinez, J. C., & Martínez, P. (1992) · The Journal of Pathology · doi:10.1002/path.1711660305 · Cited by 96
Aging and cancer: The role of stromal interactions with epithelial cells
Rinehart, C. A., & Torti, V. R. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199704)18:4 · Cited by 45
Overexpression of p53 protein in basal cell carcinomas of human skin.
Shea, C. R., McNutt, N. S., Volkenandt, M., Lugo, J., Prioleau, P. G., & Albino, A. P. (1992) · PubMed Central · Cited by 95
p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression
Soini, Y., Turpeenniemi-Hujanen, T. M., Kamel, D., Autio‐Harmainen, H., Risteli, J., Risteli, L., Nuorva, K., Pääkkö, P. K., & Vähäkangas, K. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.475 · Cited by 95
Guanine nucleotide biosynthesis is regulated by the cellular p53 concentration.
Sherley, J. L. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54302-7 · Cited by 95
p53 protein expression in breast cancer as related to histopathological characteristics and prognosis
Lipponen, P., Ji, H., Aaltomaa, S. H., Syrjänen, S., & Syrjänen, K. J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550110 · Cited by 95
mdm2: a bridge over the two tumour suppressors, p53 and Rb
Yap, D., Hsieh, J.-K., Chan, F., & Lü, X. (1999) · Oncogene · doi:10.1038/sj.onc.1202954 · Cited by 93
Nonrandom duplication of the chromosome bearing a mutated Ha-ras-1 allele in mouse skin tumors.
Bianchi, A. B., Aldaz, C. M., & Conti, C. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6902 · Cited by 94
p53 and c‐erbB‐2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder
Kamel, D., Pääkkö, P. K., Nuorva, K., Vähäkangas, K., & Soini, Y. (1993) · The Journal of Pathology · doi:10.1002/path.1711700111 · Cited by 94
Activated H-ras Rescues E1A-Induced Apoptosis and Cooperates with E1A To Overcome p53-Dependent Growth Arrest
Lin, H.-J. L., Eviner, V. T., Prendergast, G. C., & White, E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4536 · Cited by 94
Genetic and cellular basis of multistep carcinogenesis
Boyd, J. A., & Barrett, J. C. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90028-z · Cited by 97
Dissociation of Rb-binding and anchorage-independent growth from immortalization and tumorigenicity using SV40 mutants producing N-terminally truncated large T antigens
Thompson, D. L., Kalderon, D., Smith, A. E., & Tevethia, M. J. (1990) · Virology · doi:10.1016/0042-6822(90)90375-2 · Cited by 94
The p53 circuit board
Sullivan, K. D., Gallant‐Behm, C. L., Henry, R. E., Fraikin, J.-L., & Espinosa, J. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.01.004 · Cited by 96
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
Monti, P., Menichini, P., Speciale, A., Cutrona, G., Fais, F., Taìana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593383 · Cited by 98
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.
Felix, C. A., Nau, M. M., Takahashi, T., Mitsudomi, T., Chiba, I., Poplack, D., Reaman, G. H., Cole, D. E., Letterio, J. J., & Whang‐Peng, J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115630 · Cited by 92
Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification.
Imamura, J., Bartram, C., Berthold, F., Harms, D., Nakamura, H., & Koeffler, H. P. (1993) · PubMed · Cited by 92
The clinical significance of p53 aberrations in human tumours
Bòsari, S., & Viale, G. (1995) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00203389 · Cited by 90
p53 protein expression in non‐neoplastic lesions and benign and malignant neoplasms of soft tissue
Tos, A. P. D., Doglioni, C., Laurino, L., Barbareschi, M., & Fletcher, C. D. �. (1993) · Histopathology · doi:10.1111/j.1365-2559.1993.tb00068.x · Cited by 92
TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)
Tornesello, M. L. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5448 · Cited by 105
The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger
Boddy, M. N., Freemont, P. S., & Borden, K. L. B. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90020-5 · Cited by 91
Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma
Eccles, D., Brett, L., Lessells, A. M., Gruber, L., Lane, D. P., Steel, C., & Leonard, R. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.8 · Cited by 91
Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions.
Wee, A., Teh, M., & Raju, G. C. (1994) · Journal of Clinical Pathology · doi:10.1136/jcp.47.5.453 · Cited by 90
Repression of the basal c-fos promoter by wild-type p53
Kley, N., Chung, R. Y., Fay, S., Loeffler, J., & Seizinger, B. R. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.15.4083 · Cited by 90
Genes induced by serum growth factors
Lau, L. F., & Nathans, D. (1991) · Molecular aspects of cellular regulation · doi:10.1016/b978-0-444-81382-4.50019-0 · Cited by 88
Structure–based rescue of common tumor–derived p53 mutants
Wieczorek, A. M., Waterman, J. L. F., Waterman, M. J. F., & Halazonetis, T. D. (1996) · Nature Medicine · doi:10.1038/nm1096-1143 · Cited by 88
Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma
Tomizawa, Y., Kohno, T., Fujita, T., Kiyama, M., Saito, R., Noguchi, M., Matsuno, Y., Hirohashi, S., Yamaguchi, N., Nakajima, T., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202384 · Cited by 89
Tumor Suppressor p53 Mutations and Breast Cancer: A Critical Analysis
Ozbun, M. A., & Butel, J. S. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60252-3 · Cited by 89
Second malignant neoplasms occuring in survivors of osteosarcoma
Pratt, C. B., Meyer, W. H., Luo, X., Cain, A. M., Kaste, S. C., Pappo, A. S., Rao, B. N., Fleming, I. D., & Jenkins, J. J. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970901)80:5 · Cited by 76
The p53 tumor suppressor gene
Micelli, G., Donadeo, A., & Quaranta, M. (1992) · Cell Biophysics · doi:10.1007/bf02789475 · Cited by 88
Gain-of-function mutant p53: history and speculation
Bargonetti, J., & Prives, C. L. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz067 · Cited by 87
Salivary gland malignant myoepithelioma
Nagao, T., Sugano, I., Ishida, Y., Tajima, Y., Matsuzaki, O., Konno, A., Kondō, Y., & Nagao, K. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981001)83:7 · Cited by 282
Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis
Marcellus, R. C., Teodoro, J. G., Wu, T., Brough, D. E., Ketner, G. W., Shore, G. C., & Branton, P. E. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.6207-6215.1996 · Cited by 87
Restoration of wild‐type p53 function in human cancer: Relevance for tumor therapy
Bossi, G., & Sacchi, A. (2007) · Head & Neck · doi:10.1002/hed.20529 · Cited by 86
Overexpression of P53 in head and neck cancer
Watling, D. L., Gown, A. M., & Coltrera, M. D. (1992) · Head & Neck · doi:10.1002/hed.2880140603 · Cited by 87
Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
Li, X., Liu, Y., & Tian, H. (2018) · Bioinorganic Chemistry and Applications · doi:10.1155/2018/8276139 · Cited by 86
Epstein-barr virus in patients with polymorphic reticulosis (lethal midline granuloma) from china and japan
Mishima, K., Horiuchi, K., Kojya, S., Takahashi, H., Ohsawa, M., & Aozasa, K. (1994) · Cancer · doi:10.1002/1097-0142(19940615)73:12 · Cited by 29
Molecular pathogenesis of thyroid cancer
Segev, D. L., Umbricht, C. B., & Zeiger, M. A. (2003) · Surgical Oncology · doi:10.1016/s0960-7404(03)00037-9 · Cited by 87
Tissue‐specific expression of p53 in transgenic mice is regulated by intron sequences
Lozano, G., & Levine, A. J. (1991) · Molecular Carcinogenesis · doi:10.1002/mc.2940040103 · Cited by 86
Self-citation
Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin.
Ren, Z. P., Ahmadian, A., Pontén, F., Nistér, M., Berg, C., Lundeberg, J., Uhlén, M., & Pontén, J. (1997) · Europe PMC (PubMed Central) · Cited by 86
Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators
Roemer, K. (1999) · Biological Chemistry · doi:10.1515/bc.1999.108 · Cited by 86
RB and the cell cycle: Entrance or exit?
Cooper, J. A., & Whyte, P. (1989) · Cell · doi:10.1016/0092-8674(89)90495-9 · Cited by 86
Unfinished Stories on Viral Quasispecies and Darwinian Views of Evolution
Más, A., López‐Galíndez, C., Cacho, I., Gómez, J., & Martı́nez, M. Á. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.02.005 · Cited by 86
Probing p53 biological functions through the use of genetically engineered mouse models
Attardi, L. D., & Donehower, L. A. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.08.022 · Cited by 89
Expression and interactions of human adenovirus oncoproteins
Boulanger, P. A., & Blair, G. E. (1991) · Biochemical Journal · doi:10.1042/bj2750281 · Cited by 85
Mechanisms of Signal Transduction to the Cell Nucleus
Nigg, E. A. (1990) · Advances in cancer research · doi:10.1016/s0065-230x(08)60471-6 · Cited by 85

Authors: Finlay, C. A., Hinds, P. W., & Levine, A. J.
Affiliations: Princeton University (US)
ORCID: Hinds, Philip W.
Levine, Arnold J.
Venue: Cell
Publisher: Elsevier BV
Published: 1989-06
Volume: 57
Issue: 7
Pages: 1083-1093
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/0092-8674(89)90045-7
OpenAlex: W2163565167
Cited by: 1,987
References: 70
Citations by year: 2026: 14 · 2025: 12 · 2024: 25 · 2023: 27 · 2022: 20 · 2021: 34 · 2020: 37 · 2019: 31 · 2018: 29 · 2017: 29 · 2016: 28 · 2015: 12 · 2014: 28 · 2013: 26 · 2012: 38
FWCI: 79.38
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P01CA041086, P01-CA41086-03)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: tumor suppressor, oncogenic transformation, adenovirus E1A, oncogenic Ras, mutant p53, p53 expression, rat embryo fibroblasts, transformed foci, tumor suppressor function
MeSH terms: Animals, Antigens, Polyomavirus Transforming, Cell Line, Cell Transformation, Neoplastic, Cells, Cultured, Gene Expression Regulation, Neoplasm Proteins, Oncogene Proteins, Viral, Phosphoproteins, Proto-Oncogene Proteins, Genes, ras, Transfection, Tumor Suppressor Protein p53, Adenovirus Early Proteins, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The p53 proto-oncogene can act as a suppressor of transformation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks